<DOC>
	<DOCNO>NCT02166359</DOCNO>
	<brief_summary>Patients chronic kidney disease ( CKD ) markedly high prevalence cardiovascular disease ( CVD ) general population . Dyslipidemia consider major cause CVD patient CKD . Especially peritoneal dialysis ( PD ) patient , use glucose osmotic agent PD solution associate variety metabolic consequence range acute hyperglycemia hyperinsulinemia dyslipidemia weight gain . Among lipid abnormality , hypertriglyceridemia common PD patient . A study show patient high triglyceride level insulin-resistant normal triglyceride level . Insulin resistant associate atherogenic response represent high plasma level monocyte chemotactic protein-1 large cohort dialysis patient . Therefore , high triglyceride level may play important role CV outcome PD patient . PD solution decrease triglyceride level essential PD patient . Icodextrin , starch-derived high molecular weight glucose polymer found increase ultrafiltration compare glucose solution . Furthermore , low peritoneal absorption icodextrin , catabolize maltose , considerably reduce caloric uptake . Therefore , icodextrin may additional favorable effect triglyceride level . There several study regard effect icodextrin triglyceride level PD patient . However , outcomes controversial , study show association icodextrin triglyceride change , even others show positive result also study design limitation non-randomized study secondary primary outcome . It clear effect icodextrin triglyceride especially PD patient without diabetes . The investigator therefore want conduct randomize , cross-over , control multicenter trial compare icodextrin solution glucose solution PD patient without diabetes , focus triglyceride change .</brief_summary>
	<brief_title>Effect Extraneal ( Icodextrin ) Triglyceride Levels PD Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Icodextrin</mesh_term>
	<criteria>PD patient agree write informed consent Incident prevalent PD patient dialysis least 3month PD patient treat two glucose solution include 2.5 % 4.25 % dextrose solution least 4hour PD patient allergy starchbased polymer PD patient glycogen storage disease PD patient maltose isomaltose intolerance PD patient active alcohol/substance abuse Pregnant nursing PD patient PD patient episode peritonitis active systemic infection within 4weeks study initiation PD patient newly prescribe lipidlowering medication , include statin , omega3 fatty acid sevelamer hydrochloride within 3 month randomization PD patient triglyceride level &gt; 500 mg/dL/L &lt; 100 mg/dL PD patient albumin level &lt; 3.0 gram/dL PD patient treat automated PD PD patient treat treat icodextrin PD solution</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Icodextrin</keyword>
	<keyword>Triglyceride</keyword>
</DOC>